In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: The influence on cellular response to hepatocyte Growth Factor

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Sasi, Walid ^a   Ye, Lin ^b   Jiang, Wen G ^b   Sharma, Anup K ^a   Mokbel, Kefah ^a,c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Princess Grace Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE C GAMMA1; SCATTER FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 7; UNCLASSIFIED DRUG; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; ESTRANE DERIVATIVE; NUCLEAR PROTEIN; PHOSPHOLIPASE C GAMMA; SCATTER FACTOR RECEPTOR; SOCS7 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BREAST CANCER; BREAST CANCER CELL LINE; ELECTRICAL CELL IMPEDANCE SENSING ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; METASTASIS; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE SILENCING; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; ESTRENES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; MCF-7 CELLS; MICE; NUCLEAR PROTEINS; PHOSPHOLIPASE C GAMMA; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929433594     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/648040     Document Type: Article

References (30)

1. W. Sasi, W. G. Jiang, A. Sharma, and K. Mokbel, "Higher expression levels of SOCS 1, 3, 4, 7 are associated with earlier tumour stage and better clinical outcome in human breast cancer, " BMC Cancer, vol. 10, article 178, 2010.
2. P. C. Ma, M. S. Tretiakova, A. C. MacKinnon et al. , "Expression andmutational analysis ofMET in human solid cancers, " Genes Chromosomes and Cancer, vol. 47, no. 12, pp. 1025-1037, 2008.
3. E. Lengyel, D. Prechtel, J. H. Resau et al. , "c-Met overexpression in node-positive breast cancer identifies patientswith poor clinical outcome independent ofHer2/neu, " International Journal of Cancer, vol. 113, no. 4, pp. 678-682, 2005.
4. G. Edakuni, E. Sasatomi, T. Satoh, O. Tokunaga, and K. Miyazaki, "Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma, " Pathology International, vol. 51, no. 3, pp. 172-178, 2001.
5. A. B. Tuck, M. Park, E. E. Sterns, A. Boag, and B. E. Elliott, "Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma, "TheAmerican Journal of Pathology, vol. 148, no. 1, pp. 225-232, 1996.
6. L. Jin, A. Fuchs, S. J. Schnitt et al. , "Expression of scatter factor and c-met receptor in benign and malignant breast tissue, " Cancer, vol. 79, no. 4, pp. 749-760, 1997.
7. J. Yamashita, M. Ogawa, S. Yamashita et al. , "Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer, " Cancer Research, vol. 54, no. 7, pp. 1630-1633, 1994.
8. M. I. Gallego, B. Bierie, and L. Hennighausen, "Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation ofmultiple signal transduction pathways, " Oncogene, vol. 22, no. 52, pp. 8498-8508, 2003.
9. C. L. Arteaga, M. D. Johnson, G. Todderud, R. J. Coffey, G. Carpenter, and D. L. Page, "Elevated content of the tyrosine kinase substrate phospholipase C-1 in primary human breast carcinomas, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 23, pp. 10435-10439, 1991.
10. J. Kassis, J. Moellinger, H. Lo, N. M. Greenberg, H. Kim, and A. Wells, "A role for phospholipase C-mediated signaling in tumor cell invasion, " Clinical Cancer Research, vol. 5, no. 8, pp. 2251-2260, 1999.
11. K. Matuoka, H. Miki, K. Takahashi, and T. Takenawa, "A novel ligand for an SH3 domain of the adaptor protein Nck bearsan SH2 domain and nuclear signaling motifs, " Biochemical and Biophysical Research Communications, vol. 239, no. 2, pp. 488-492, 1997.
12. R. Nishimura, W. Li, A. Kashishian et al. , "Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor, " Molecular and Cellular Biology, vol. 13, no. 11, pp. 6889-6896, 1993.
13. M. Lettau, J. Pieper, and O. Janssen, "Nck adapter proteins: functional versatility in T cells, " Cell Communication and Signaling, vol. 7, article 1, 2009.
14. K. S. Kochhar and A. P. Iyer, "Hepatocyte growth factor induces activation of Nck and phospholipase C- in lung carcinoma cells, " Cancer Letters, vol. 104, no. 2, pp. 163-169, 1996.
15. M. Johnson, K. Kochhar, T. Nakamura, and A. Iyer, "Hepatocyte growth factor-induced signal transduction in two normal mouse epithelial cell lines, " Biochemistry and Molecular Biology International, vol. 36, no. 3, pp. 465-474, 1995.
16. B. E. Kremer, L. A. Adang, and I. G. Macara, "Septins regulate actin organization and cell-cycle arrest through nuclear accumulation of NCK mediated by SOCS7, " Cell, vol. 130, no. 5, pp. 837-850, 2007.
17. N. Martens, M. Wery, P. Wang et al. , "The suppressor of cytokine signaling (SOCS)-7 interacts with the actin cytoskeleton through vinexin, " Experimental Cell Research, vol. 298, no. 1, pp. 239-248, 2004.
18. E. Y. Skolnik, A. Batzer, N. Li et al. , "The function of GRB2 in linking the insulin receptor to Ras signaling pathways, " Science, vol. 260, no. 5116, pp. 1953-1955, 1993.
19. J. P. Eder, G. F. VandeWoude, S. A. Boerner, and P. M. Lorusso, "Novel therapeutic inhibitors of the c-Met signaling pathway in cancer, " Clinical Cancer Research, vol. 15, no. 7, pp. 2207-2214, 2009.
20. A. S. Banks, J. Li, L. McKeag et al. , "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans, " Journal of Clinical Investigation, vol. 115, no. 9, pp. 2462-2471, 2005.
21. D. L. Krebs, R. T. Uren, D. Metcalf et al. , "SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation, " Molecular and Cellular Biology, vol. 22, no. 13, pp. 4567-4578, 2002.
22. D. Ge, A. C. Gao, Q. Zhang, S. Liu, Y. Xue, and Z. You, "LNCaP prostate cancer cellswith autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling, " The Prostate, vol. 72, no. 12, pp. 1306-1316, 2012.
23. J. Knisz, A. Banks, L. McKeag, D. D. Metcalfe, P. B. Rothman, and J. M. Brown, "Loss of SOCS7 in mice results in severe cutaneous disease and increased mast cell activation, " Clinical Immunology, vol. 132, no. 2, pp. 277-284, 2009.
24. J. K. Howard and J. S. Flier, "Attenuation of leptin and insulin signaling by SOCS proteins, " Trends in Endocrinology and Metabolism, vol. 17, no. 9, pp. 365-371, 2006.
25. N. Martens, G. Uzan, M. Wery, R. Hooghe, E. L. Hooghe-Peters, and A. Gertler, "Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation, " Journal of Biological Chemistry, vol. 280, no. 14, pp. 13817-13823, 2005.
26. W. G. Jiang, G. Davies, T. A. Martin et al. , "Targetingmatrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy, " Clinical Cancer Research, vol. 11, no. 16, pp. 6012-6019, 2005.
27. M. K. Evans, C. Yu, A. Lohani et al. , "Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals, " Oncogene, vol. 26, no. 13, pp. 1941-1948, 2007.
28. W. Sasi, L. Ye, W. G. Jiang, K. Mokbel, and A. Sharma, "Observations on the effects of suppressor of cytokine signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to insulin like growth factor I (IGF-I), " Clinical and Translational Oncology, vol. 16, no. 5, pp. 476-487, 2014.
29. W. G. Jiang, D. Grimshaw, J. Lane et al. , "A hammerhead ribozyme suppresses expression of hepatocyte growth factor/ scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells, " Clinical Cancer Research, vol. 7, no. 8, pp. 2555-2562, 2001.
30. L. Abalsamo, F. Spadaro, G. Bozzuto et al. , "Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells, " Breast Cancer Research, vol. 14, no. 2, article R50, 2012.